8-亚甲基-1,4-二噁螺[4.5]癸烷 | 51656-90-7

• 物质功能分类: 化学试剂 - 硅烷试剂
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 8-亚甲基-1,4-二噁螺[4.5]癸烷
• 中文别名: 8-亚甲基-1,4-二氧螺环[4,5]癸烷
• 英文名称: 8-methylene-1,4-dioxaspiro[4.5]decane
• 英文别名: 8-methylidene-1,4-dioxaspiro[4,5]decane；8-methylidene-1,4-dioxaspiro[4.5]decane
• CAS: 51656-90-7
• 化学式: C₉H₁₄O₂
• mdl: MFCD07779440
• 分子量: 154.209
• InChiKey: BCWKBPCNPHCCQS-UHFFFAOYSA-N

物化性质

• 沸点：
  221.4±40.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 8-Methylidene-1,4-dioxaspiro[4.5]decane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 8-Methylidene-1,4-dioxaspiro[4.5]decane
CAS number: 51656-90-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H14O2
Molecular weight: 154.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  8-亚甲基-1,4-二噁螺[4.5]癸烷 在 palladium on activated charcoal Davison sponge Ni 、 硼烷 、 氢气 、 sodium methylate 、 pyridinium chlorochromate 作用下， 反应 36.75h， 生成 4-[2-(1,4-Dioxa-spiro[4.5]dec-8-yl)-ethyl]-benzoic acid tert-butyl ester
  参考文献：
  名称：

  (6R,6S)-5,8,10-Trideaza-5,6,7,8-tetrahydrofolate and (6R,6S)-5,8,10-trideaza-5,6,7,8-tetrahydropteroyl-L-ornithine as potential antifolates and antitumor agents. 35

  摘要：

  (6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰酸通过多步反应由4,4-(环氧乙烷氧基)-环己酮和[4-(叔丁基氧基羰基)苄基]三苯基𬭸溴化物合成，并进一步转化为(6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰-L-谷氨酸和(6R,6S)-5,8,10-三去氮-5,6,7,8-四氢蝶酰-L-精氨酸。化合物1被发现是部分纯化的鼠肝叶酸多谷氨酸合成酶（FPGS）的良好底物，其米氏常数（Km = 15 μM）与报道的还原型叶酸底物（6S）-5,6,7,8-四氢蝶酰-L-谷氨酸以及(6R,6S)-5,10-二去氮-5,6,7,8-四氢蝶酰-L-谷氨酸（DDATHF）的值相当。然而，与具有强细胞毒性的DDATHF形成鲜明对比的是，化合物1在高达100 μM的浓度下未能抑制肿瘤细胞的生长。这些结果表明，DDATHF中位于8号位的NH对于细胞毒性活性至关重要，但并非多谷氨酸化的必要条件。与1作为FPGS的良好底物类似，精氨酸类似物2证明是迄今为止发现的对该酶的较强竞争性抑制剂之一，其Ki值为10 μM。尽管2与5,6,7,8-四氢蝶酰-L-精氨酸（H4PteOrn）相比结合亲和力较低，但在N5、N8和N10位被碳取代的情况下，仍观察到显著的FPGS抑制作用。这表明，FPGS对环B和桥区的生物等价替代表现出一定的耐受性。化合物1和2在高达100 μM的浓度下均未显示出抑制细胞生长的活性。作为潜在前药的化合物2的Nδ半邻苯二甲酰衍生物也未表现出活性。

  DOI：

  10.1021/jm00123a037
• 作为产物：
  描述：

  1,4-环己二酮双乙二醇二缩酮 在 水 作用下， 以 溶剂黄146 、 二甲基亚砜 、 三氟乙酸 、 苯 为溶剂， 反应 16.0h， 生成 8-亚甲基-1,4-二噁螺[4.5]癸烷
  参考文献：
  名称：

  Carbocyclic thromboxane A2

  摘要：

  DOI：

  10.1021/ja00524a028
• 作为试剂：
  描述：

  2-(4-methylene-1-piperidyl)-3-nitropyridine 、 Lithium bistrimethylsilylamide 、 锂 、 1,4-环己二酮单乙二醇缩酮 、 1-(3-nitropyridin-2-yl)piperidin-4-one 在 8-亚甲基-1,4-二噁螺[4.5]癸烷 、 Petroleum Ether EtOAc 作用下， 生成 8-亚甲基-1,4-二噁螺[4.5]癸烷
  参考文献：
  名称：

  Spiroheterocyclic compounds as mGlu5 antagonists

  摘要：

  本发明涉及使用选择性拮抗剂治疗哺乳动物下尿路神经肌肉功能障碍的方法。提供了一种通过给哺乳动物投予选择性mGlu5受体拮抗剂来治疗下尿路神经肌肉功能障碍的方法。该选择性mGlu5受体拮抗剂可以单独或与一种或多种其他治疗剂联合使用来治疗此类疾病。还提供了用于治疗偏头痛和胃食管反流病（GERD）的选择性mGlu5受体拮抗剂的方法。同时还提供了用于鉴定对治疗哺乳动物下尿路神经肌肉功能障碍有用的选择性mGlu5受体拮抗剂的方法。

  公开号：

  US08580962B2

文献信息

• [EN] METHODS OF TREATMENT OF AMYLOIDOSIS USING ASPARTYL-PROTEASE INIHIBITORS<br/>[FR] PROCEDES DE TRAITEMENT D'AMYLOIDOSE UTILISANT DES INHIBITEURS DE PROTEASE ASPARTYLE
  申请人：ELAN PHARM INC

  公开号：WO2005070407A1

  公开（公告）日：2005-08-04

  The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein.

  这项发明涉及乙酰2-羟基-1,3-二氨基螺环己烷及其衍生物，可用于治疗与淀粉样变性相关的疾病、疾病和症状。淀粉样变性是指与A-beta蛋白异常沉积相关的一系列疾病、疾病和症状。
• [EN] HEPATITIS C INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE L'HÉPATITE C
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2013026163A1

  公开（公告）日：2013-02-28

  A compound of formula (I) useful for the treatment or prevention of hepatitis C viral infection, (Formula (I)) wherein: X1 and X2 are each independently CRB or N; RB is H, (C1-6)alkyl, (C1-6)haloalkyl, halo. -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; R1 and R2 are each independently (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R1 and R2, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; RA is -C(=O)N(R3)(R4), -C(=O)O(R4), heterocyclyl or heteroaryl, wherein each said heterocyclyl and heteroaryl is optionally substituted 1 to 3 times with R41; R5 and R6 are each independently H or (C1-6)alkyl optionally mono- or di-substituted with -O-(C1-6)alkyl, NH2, NH(C1-6)alkyl or N((C1-6)alkyl)2; or R5 and R6, together with the carbon to which they are attached, are linked to form a (C3-7)cycloalkyl group or a 3- to 7-membered heterocyclyl, said cycloalkyl and heterocyclyl being optionally mono- or di-substituted with -(C1-6)alkyl; and n is 0, 1 or 2.

  一种化合物，其化学式为（I），用于治疗或预防丙型肝炎病毒感染，其中：X1和X2分别独立地为CRB或N；RB为H，（C1-6）烷基，（C1-6）卤代烷基，卤基，-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；R1和R2分别独立地为（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R1和R2与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；RA为-C（=O）N（R3）（R4），-C（=O）O（R4），杂环烷基或杂芳基，其中每个所述杂环烷基和杂芳基可选择地用R41取代1至3次；R5和R6分别独立地为H或（C1-6）烷基，可选择地单取代或双取代为-O-（C1-6）烷基，NH2，NH（C1-6）烷基或N（（C1-6）烷基）2；或者R5和R6与它们连接的碳原子一起形成（C3-7）环烷基或3-至7-成员杂环烷基，所述环烷基和杂环烷基可选择地单取代或双取代为-（C1-6）烷基；n为0、1或2。
• Synthesis of Functionalized Difluorocyclopropanes: Unique Building Blocks for Drug Discovery
  作者：Roman M. Bychek、Vadym V. Levterov、Iryna V. Sadkova、Andrey A. Tolmachev、Pavel K. Mykhailiuk

  DOI：10.1002/chem.201705708

  日期：2018.8.22

  Difluorocyclopropane‐containing building blocks for drug discovery were synthesized from the functionalized alkenes and TMSCF3/NaI. Novel fluorinated acids, amines, amino acids, alcohols, ketones and sulfonyl chlorides were obtained.

  由功能化烯烃和TMSCF 3 / NaI合成了用于药物发现的含二氟环丙烷的结构单元。获得了新颖的氟化酸，胺，氨基酸，醇，酮和磺酰氯。
• [EN] PYRAZOLE CARBOXAMIDE COMPOUNDS FOR TREATMENT OF HBV<br/>[FR] COMPOSÉS DE PYRAZOLE CARBOXAMIDE POUR LE TRAITEMENT DU VHB
  申请人：ASSEMBLY BIOSCIENCES INC

  公开号：WO2021216661A1

  公开（公告）日：2021-10-28

  The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.

  本公开内容部分提供了吡唑甲酰胺化合物及其药物组合物，用于破坏乙型肝炎病毒（HBV）核心蛋白组装，以及治疗乙型肝炎（HBV）感染的方法。
• Further Studies on the Direct Synthesis of<i>α</i>,<i>β</i>-Unsaturated Ketimines and<i>α</i>,<i>β</i>-Enones by Chemoselective Dehydrative Addition of Functionalized Alkenes to Secondary Amides
  作者：Pei-Qiang Huang、Ying-Hong Huang

  DOI：10.1002/cjoc.201600700

  日期：2017.5

  including ester, α,β‐unsaturated ester, uncongested ketone groups, as well as enol derivatives of acetaldehyde such as enol ether and enamides. The electrophilic partner has been extended from N‐(2,6‐dimethylphenyl) and N‐methyl amides to N‐n‐butyl, and N‐cyclohexyl amides. The results demonstrated that the method can be used to synthesize a number of functionalized α,β‐unsaturated ketimines and α,β‐enones

  本文描述的是对C-H烷基亚氨基化和烯烃与仲酰胺酰化的扩展研究的结果。亲核伴侣已扩展至涵盖一系列带有官能团的官能化烯烃，这些官能团包括酯，α，β-不饱和酯，未拥挤的酮基以及乙醛的烯醇衍生物，例如烯醇醚和酰胺。亲电子分子已从N-（2,6-二甲基苯基）和N-甲基酰胺扩展到N-正丁基和N-环己基酰胺。结果表明，该方法可用于合成许多功能化的α，β有效，高产且单锅方式的不饱和酮亚胺和α，β烯酮。该方法用于（E）-6-苯乙烯基四氢-2 H-吡喃-2-酮（5）的简明合成中，该中间体是一系列苯乙烯基内酯天然产物的直接中间体，包括（±）-goniothalamine（6），（±）-邻苯二酚氧化胺（7），（±）-邻苯二酚（8），（±）-leiocarpin A（9），（±）-9-脱氧goniopypyrone（10）和（±）-7- Epi gon二醇（11）。